Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus ZYFREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus ZYFREL.
IMPOYZ vs ZYFREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
ZYFREL is a selective serotonin reuptake inhibitor (SSRI) that inhibits serotonin reuptake at the presynaptic terminal, increasing serotonergic neurotransmission in the CNS.
100 mg orally twice daily
500 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
12-15 hours, terminal elimination half-life; prolonged in renal impairment (up to 30 hours), requiring dose adjustment.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Renal: 65% unchanged; biliary/fecal: 30% as metabolites; 5% other.
Category C
Category C
Unknown
Unknown